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Abstract.21
Background:The major genetic risk factor for late onset Alzheimer’s disease (AD) is theAPOE-4 allele. However,APOE-4
homozygosity is not fully penetrant, suggesting co-occurrence of additional genetic variants.
22
23
Objective: To identify genetic factors that, next to APOE-4 homozygosity, contribute to the development of AD.24
Methods: We identified a family with nine AD patients spanning four generations, with an inheritance pattern suggestive
of autosomal dominant AD, with no variants in PSEN1, PSEN2, or APP. We collected DNA from four affected and seven
unaffected family members and performed exome sequencing on DNA from three affected and one unaffected family
members.
25
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Results: All affected family members were homozygous for the APOE-4 allele. Statistical analysis revealed that AD onset
in this family was significantly earlier than could be expected based on APOE genotype and gender. Next to APOE-4
homozygosity, we found that all four affected family members carried a rare variant in the VPS10 domain of the SORL1 gene,
associated with APP processing and AD risk. Furthermore, three of four affected family members carried a rare variant in
the TSHZ3 gene, also associated with APP processing. Affected family members presented between 61 and 74 years, with
variable presence of microbleeds/cerebral amyloid angiopathy and electroencephalographic abnormalities.
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Conclusion: We hypothesize that next to APOE-4 homozygosity, impaired SORL1 protein function, and possibly impaired
TSHZ3 function, further disturbed A processing. The convergence of these genetic factors over several generations might
clarify the increased AD penetrance and the autosomal dominant-like inheritance pattern of AD as observed in this family.
35
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INTRODUCTION35
Alzheimer’s disease (AD) is a complex and het-36
erogeneous neurodegenerative disease. AD incidence37
increases with age, and about one third of the38
population aged 85 years and older is estimated39
to have AD [1]. AD is typically characterized by40
deficits in short-term memory, language, praxis, and41
visuospatial and executive functioning, eventually42
resulting in global cognitive decline. Despite intense43
research during past decades, the exact causes of44
AD are not yet understood. The leading hypoth-45
esis of AD pathogenesis is the amyloid cascade46
hypothesis, which proposes that aberrant process-47
ing of the amyloid- protein precursor (APP) leads48
to increased production of amyloid- (A) peptide49
in the brain cells (reviewed in [2]). In turn, A50
peptides are misfolded and accumulate into pro-51
tein aggregates, ultimately leading to the formation52
of neurotoxic amyloid plaques that disrupt normal53
cellular processes. Genetic mutations in autosomal54
dominant AD are detected in genes involved in A55
processing: the amyloid precursor protein (APP),56
which is the source of A, and the presenilins57
(PSEN1 and PSEN2) involved in APP-processing58
[3–5].59
Twin studies estimated that∼60–80% of late onset60
AD risk is heritable with the remainder being envi-61
ronmental (LOAD, age at onset >65 years) [6]. By62
far the most important susceptibility gene for late63
onset AD is the Apolipoprotein E (APOE) gene64
[7]. Next to functions related with lipid and choles-65
terol processing, the protein product of the APOE66
gene, ApoE, is suggested to be involved in the clear-67
ance of A from the brain (reviewed in [2]). The68
APOE gene contains three common allelic variants69
(APOE-ε2, APOE-ε3, APOE-ε4), which encode the70
ApoE2, ApoE3, and ApoE4 protein isoforms. Opti-71
mal A clearance efficiency has been suggested to72
explain the neuroprotective nature of the ApoE2 iso-73
form relative to the most common ApoE3 isoform,74
whereas presumably, the impaired A clearance by75
the ApoE4 isoform explains the increased AD risk for76
APOE-ε4 allele carriers [2]. In fact, more than 30% of77
the AD cases in the population can be attributed to the78
APOE-4 allele (population attributable fraction), 79
whereas at most 8% of AD cases can be attributed 80
to any of the genes detected in a genome-wide asso- 81
ciation studies [8]. 82
Carrying the APOE-4 allele predisposes for AD 83
in a dose-dependent manner: compared to non- 84
APOE-4 carriers, AD risk is increased 3–5 fold 85
for heterozygous APOE-4 carriers, and 10-15-fold 86
for homozygous APOE-4 carriers [9]. However, 87
despite this large effect size, the penetrance of APOE- 88
4 homozygosity is incomplete. The chance that 89
APOE-4 homozygotes develop AD before the age 90
of 85 years is 50% for males and 60% for females 91
[10]. Some APOE-4 homozygotes reach ages over 92
100 years while retaining their cognitive health [11]. 93
This suggests that next to being homozygous for the 94
APOE-4 allele, additional genetic modifiers are nec- 95
essary for the development of AD. To our knowledge, 96
it has never been investigated whether other genetic 97
variants co-occur with APOE-4 homozygosity in 98
AD patients. 99
We identified a family with AD patients with a 100
relatively early onset of disease, spanning at least 101
four generations, with an inheritance pattern that sug- 102
gests autosomal dominant AD. DNA was available 103
from four affected and 7 unaffected family members, 104
from the two youngest generations. We found that 105
all four genetically tested affected family members 106
were homozygous for the APOE-4 allele. There- 107
fore, this family provided the unique opportunity to 108
investigate additional genetic variants next to APOE- 109
4 homozygosity, which might have contributed to 110
AD. We describe the pedigree, the phenotype of 111
the affected family members, the outcome of whole 112
exome sequencing, and the segregation of the genetic 113
variants. 114
MATERIAL AND METHODS 115
Pedigree and participants 116
We describe a family comprising nine individuals 117
with AD symptoms who span four generations within 118
one pedigree (Fig. 1, Supplementary Table 1A): eight 119
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Fig. 1. Pedigree of family with four generations of AD patients. Black diamonds: Family members affected with AD; White diamonds:
non-affected family members at time of death or last screening; Grey diamond: no consent to reveal disease history; “W” in diamond: family
member included in whole exome sequencing; ‘n’ in a diamond, multiple family members merged and represented as one; AD [number],
Alzheimer’s disease with age at diagnosis; d [number], age at death. E4/E4, APOE-4 homozygosity; SORL1+, subject is positive for the
variant c.2012A>G in SORL1; TSHZ3+ subject is positive for the variant c.707C>T in TSHZ3; Grey text, DNA was not available for these
family members, we estimated the chances that an individual has a given APOE genotype, based on (i) frequency of genotype combinations
in the Dutch population, (ii) Mendelian inheritance patterns given the genotype distribution within the family structure and (iii) disease
status. The chances for APOE genotypes do not add up to 100% when (smaller) chances for other APOE genotypes remain (Supplementary
Table 1). Inferred chances of carrying of SORL1 and TSHZ3 genes are based on normal Mendelian inheritance patterns; Sex is not indicated
and the order of siblings is rearranged to avoid recognition of this family and individual family members. See Supplementary Table 1 for
list of genotype/phenotype data per-family member.
were diagnosed with AD, or were reported to have120
symptoms of AD (0.2, I.1, I.3, I.4, II.1, II.3, II.4, and121
II.6) and one individual had preclinical AD (III.1).122
Multiple individuals did not present AD symptoms123
at the time of observation (youngest individuals were124
merged into III.4-III.5 to avoid recognition).125
Four family members with (preclinical) AD and126
seven of the unaffected family members (aged ≤60127
years) consented to participate in this study (II.3 and128
II.4 by consent of their proxies). Affected family129
member II.1 consented to the use of his clinical data130
for research purposes. Detailed clinical data were not131
available for the affected family members of the first132
generations (0.2, I.1, I.3, and I.4).133
Two family members with AD (II.1 and II.6) 134
and the family member with preclinical AD (III.1) 135
visited the Alzheimer center at the VU Univer- 136
sity medical center (VUmc) in the Netherlands and 137
underwent extensive standardized diagnostic work- 138
up [12]. The other affected family members (II.3 and 139
II.4) were diagnosed elsewhere in the Netherlands. 140
All diagnoses of AD were based on the NINCDS- 141
ADRDA criteria as described by McKhann et al. [13]. 142
Postmortem autopsy results of individual II.4 were 143
reviewed by our neuropathologist. The local medical 144
ethics committee of the VUmc approved the study. 145
We did not obtain consent to reveal disease history of 146
family member II.8. 147
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DNA availability148
Using common procedures, DNA was isolated149
from peripheral blood from three affected family150
members (II.3, II.6, II.4 the family member with151
preclinical AD (III.1), and the seven unaffected par-152
ticipating family members (III.2, III.3, four family153
members merged into III.4-5, and III.6).154
APOE genotyping and imputation155
For all participants with DNA available, APOE156
genotyping was performed after genomic DNA iso-157
lation from 7–10 mL EDTA blood, using a QIAxcel158
DNA Fast Analysis kit (Qiagen, Venlo, The Nether-159
lands). For the individuals comprising generation I160
and two individuals from generation II, blood sam-161
ples could not be collected. For individuals I.1, I.2,162
II.1, and II.8 APOE genotypes were determined in163
retrospect by estimating the posterior probability of164
the possibleAPOE genotypes. To this end, we applied165
Bayes theorem based on (i) the known APOE geno-166
type combinations in generations II and III, (ii) the167
population frequencies of APOE genotype combina-168
tions in the Dutch population published by LASA169
[14] (Supplementary Table 1B), and (iii) the chances170
for developing dementia for all APOE-genotype com-171
binations by age and gender published by Genin et al.172
[10] (Supplementary Table 1C).173
Analysis of AD penetrance in this family174
In a Caucasian sample comprising >17,500 cases175
and controls, Genin et al. evaluated the AD incidence176
per APOE-genotype, across age at onset and gender177
relative to baseline AD incidence [10]. These AD178
incidence distributions across age allowed us to deter-179
mine the a priori chance for any individual to develop180
AD at a certain age given their APOE genotype and181
gender. For each member of our family, the age at AD182
onset can be seen as a p-value w.r.t. to empirical the183
incidence distributions extracted from the Caucasian184
cohort.185
Persons who had not yet reached 60 years at last186
check-up were excluded, as the chance to develop187
AD before this age is very low. To account for188
the unknown age at AD onset for several fam-189
ily members, we determined a p-value by repeated190
sampling from a uniform distribution of p-values191
(truncated p-value approach [15]). We used both192
Fisher’s approach and Stouffer’s approach to com-193
bine p-values of all family members. Apart from194
their genetic dependency (which we are testing), 195
we assume that development of AD is independent 196
between family members. 197
Variant detection: Exome sequencing of four 198
family members 199
DNA of three affected family members (II.3, II.6, 200
and III.1) and the oldest unaffected family member 201
(III.2) was exome sequenced in parallel with 400 202
AD patients from the Amsterdam Dementia cohort 203
(ADC) [12] who had been diagnosed with early 204
onset dementia. The exomes were captured by the 205
Nimblegen human exome v3 capture kit, and 100 206
bp paired-end sequencing reads were generated on 207
the Illumina HiSeq 2000 platform, according to 208
the manufacturer’s protocol. We sequenced to at 209
least 40x mean coverage to ensure sufficient read 210
depth for variant calling. Reads were mapped to the 211
human reference genome sequence (UCSC hg19) 212
using Burrows-Wheeler alignment [16]. Duplicate 213
read removal, local sequence realignment and base 214
quality recalibration were performed by Picard 215
(http://picard.sourceforge.net) and with GATK 216
(Genome analysis tool kit) [17]. Variants were called 217
using GATK haplotype caller, and filtered using the 218
variant filtration tool. For each variant we set the 219
filter to PASS if the variant complied with (I) GATK 220
quality score ≥50, (II) quality over depth ≥1.5, (III) 221
Strand bias ≤60, (IV) total variant read depth ≥5.0. 222
Variants were annotated and analyzed with Cartage- 223
nia (http://www.cartagenia.com/) using a filter tree 224
specifically designed to detect variants causative 225
for a trait with an autosomal dominant inheritance 226
pattern. Since we aimed to identify rare pathogenic 227
variants, we selected variants that (i) were absent 228
in the following databases: dbSNP138 (http://www. 229
ncbi.nlm.nih.gov/projects/SNP, build 138), the 1,000 230
genome project (http://www.1000genomes.org) or 231
the National Heart Lung Blood Institute Exome 232
Variant Server (EVS) (http://evs.gs.washington. 233
edu/EVS/); (ii) had a prevalence of ≤5% in the 234
whole Amsterdam Dementia cohort; (iii) were 235
heterozygote in the 3 affected family members; and 236
(iv) were localized in a gene listed in the OMIM 237
database (http://www.omim.org). The predicted 238
functional effects of the selected sequence vari- 239
ants were assessed by PolyPhen2 (http://genetics. 240
bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/), 241
Mutation Taster (http://www.mutationtaster.org), 242
and the combined annotation dependent deletion 243
(CADD) score [18]. Information about localization 244
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and conservation of the selected variants was245
assessed by Uniprot (http://www.uniprot.org/uniprot/246
Q92673), and Alumut visual (http://www.interactive-247
biosoftware.com/alamut-visual/). Detected variants248
were confirmed by Sanger sequencing, Also, loci249
were genotyped in the all family members for whom250
DNA was available.251
RESULTS252
Clinical description253
Family member II.1 presented with complaints254
of memory decline over the previous three years255
at the age of 67. As a child, the family member256
had suffered a skull fracture. The Mini-Mental State257
Examination (MMSE) [19] score was 25/30, and neu-258
ropsychological assessment showed impairment of259
episodic memory. Routine blood analysis was nor-260
mal, except for increased serum cholesterol levels.261
Magnetic resonance imaging (MRI) showed mild262
bilateral hippocampal atrophy (medial temporal lobe263
atrophy grade 1 [20]), mild white matter hyperin-264
tensities (WMH), (Fazekas grade 1 [21], and no265
microbleeds. Electroencephalogram (EEG) revealed266
a discordant low background rhythm of 6 to 7 Hz267
with increased amounts of intermitting delta activ-268
ity in the frontotemporal regions. Cerebrospinal fluid269
(CSF) was not obtained. Based on these findings, the270
diagnosis was mild cognitive impairment (MCI) [22].271
At the age of 69, the MMSE was 21/30. Repeated272
neuropsychological assessment showed progression273
of memory impairment and impaired executive func-274
tions. At this time, MRI showed biparietal atrophy,275
with no progression of the hippocampal atrophy or276
WMH. The clinical diagnosis was probable AD [13].277
Disease progression was characterized by further278
deterioration in all cognitive domains, including the279
development of behavioral disturbances (loss of ini-280
tiative and increased irritability). This family member281
was admitted into a nursing home, suffered from282
episodes of focal neurological deficits probably due283
to recurrent strokes, and died at the age of 76 years.284
This family member gave consent to his physician to285
use his medical data for research purposes, but DNA286
was not available.287
Family member II.3 visited a geriatrician at a local288
hospital at the age of 72 because of memory com-289
plaints and fatigue for two years. This family member290
had diabetes mellitus type 2, hypertension, and dys-291
lipidemia, and had been treated for depression with292
amitriptyline for over 20 years. MMSE was 26/30 293
with disorientation in time, and neuropsychologi- 294
cal testing showed impaired recall on memory tests. 295
Computed tomography (CT) imaging showed mild 296
diffuse cortical atrophy and aspecific hypodensities 297
in the brainstem and in the basal ganglia. No formal 298
diagnosis was made at that time. A second opinion by 299
another neurologist was obtained at the age of 74. At 300
this point, the family member reported the occurrence 301
of headaches, and scored 23/30 on the MMSE. Rou- 302
tine blood analysis and EEG were normal. MRI and 303
CSF analysis were not performed. The family mem- 304
ber was diagnosed with probable AD [13]. Diagnostic 305
DNA testing revealed no variants in PSEN1, PSEN2, 306
or APP. The family member died at the age of 78 307
years (cause unspecified). 308
Family member II.4 visited a local memory clinic 309
at the age of 70, because of progressive memory 310
complaints, which initiated at the age of 59 after a 311
head trauma. The family member had suffered from 312
bacterial meningitis at the age of 69. Neuropsycho- 313
logical testing showed impairments in concentration 314
and memory, disorientation in place, and dyscalcu- 315
lia. No additional investigations were performed. The 316
family member was diagnosed with probable AD 317
[13]. The patient died at the age of 74 years most 318
likely due to a heart attack. Postmortem examination 319
of the brain confirmed the diagnosis of severe AD 320
(Braak stage 6/6 for tau and Thal phase 5/5 for A 321
with extensive cerebral amyloid angiopathy (CAA) 322
type 1 [23] (Fig. 2). 323
Family member II.6 was evaluated at our memory 324
clinic at the age of 70 years because of the positive 325
family history of dementia. At this visit, this family 326
member reported no cognitive complaints, MMSE 327
was 30/30 and neuropsychological testing showed 328
no abnormalities except for some difficulties with 329
concentration. Routine blood analysis showed no 330
abnormalities. MR imaging displayed no hippocam- 331
pal atrophy (medial temporal lobe atrophy grade 0), 332
mild WMH (Fazekas grade 1), but a high number of 333
47 microbleeds, suggestive of CAA (Fig. 3). EEG 334
showed a remarkably decreased background pat- 335
tern with reactive alpha-theta activity till 8 Hz. CSF 336
analysis showed a decreased A level of 232 ng/L 337
(reference >550 ng/L), an increased total tau level 338
of 993 ng/L (reference ≤375 ng/L), and an increased 339
level of tau phosphorylated at threonine-181 (ptau) 340
of 123 (reference ≤52 ng/L)). Based on the clini- 341
cal examination, the family member was diagnosed 342
with subjective cognitive decline [24]. During the fol- 343
lowing years, the family member developed memory 344
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a b
Fig. 2. Immunohistochemistry in temporal cortex of subject II.4. a) Immunohistochemical staining for A reveals cerebral A angiopathy
(black arrow), classical plaques (arrow head), and diffuse plaques (white arrow) in the temporal cortex (10x obj.); b) Immunohistochemical
staining for tau (mab AT8) reveals neuropil threads, (pre)tangles (arrow), and neuritic plaques (arrow head) in the temporal cortex (10x obj.).
Fig. 3. Baseline MR imaging of subject II.6. Cerebral MRI imaging of subject II.6 at age 70 showing several microbleeds (arrows). T2
weighted image.
complaints, loss of initiative, and sleeping problems.345
At the age of 74 years, MMSE was 29/30, and346
neuropsychological testing showed disturbances in347
episodic memory. MRI showed no progression of348
WMH, but the number of microbleeds had increased349
to 58. Repeated EEG displayed progressive slowing350
with theta activity of 7 Hz next to dominant posterior351
rhythms of 8 Hz. The family member was diagnosed352
with MCI. The family member was diagnosed with353
probable AD by a local geriatrician at the age of 82,354
with a MMSE score of 21 out of 30.355
Family member III.1 presented at our memory356
clinic at 58 years with memory complaints, and self-357
reported difficulties with organizing and planning.358
This family member was treated for diabetes mel- 359
litus, hypertension, and dyslipidemia. MMSE score 360
was 29/30, performance on neuropsychological test- 361
ing was normal, and MRI showed no abnormalities. 362
EEG was disturbed with a normal alpha background 363
pattern of 9 Hz, but with early intermitting left pre- 364
dominant temporal theta activity. CSF concentrations 365
showed a mildly decreased A level of 549 ng/L (ref- 366
erence >550 ng/L) and increased tau level of 435 ng/L 367
(reference ≤375 ng/L) and ptau level of 68 (ref- 368
erence ≤52 ng/L). Pittsburgh compound (PiB)-PET 369
showed increased A binding in all cortical areas. 370
F18-fluorodeoxyglucose (FDG)-PET showed a nor- 371
mal pattern of glucose metabolism. Based on clinical 372
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evaluations, the diagnosis was subjective cognitive373
decline. The abnormal AD biomarkers indicated pre-374
clinical AD, with a high likelihood of underlying AD375
pathophysiology [25]. Over the next four years, the376
family member remained clinically stable.377
Generation 0 and I: Family member I.2 died of378
cancer at age 55. Family member 1.3, a sibling of379
I.2, was reported to have dementia onset at 61. Fam-380
ily member 1.4, also a sibling of I.2, was reported to381
have cognitive decline prior to death at age 73. One382
of their parents (generation 0) was reported to have383
dementia symptoms suggestive of AD at age 80, Fam-384
ily member I.1 (partner from I.2) died at the age of385
85 years from a heart attack and was reported to have386
had dementia with AD characteristics. For these fam-387
ily members, no formal diagnosis was available at the388
time and no DNA was secured.389
Unaffected family members in generation III. The390
seven unaffected family members (III.2, III.3, III.4-5,391
and III.6) for whom DNA was available were aged 47392
to 60 years and self-reported no cognitive complaints.393
Their partner and/or a close relative confirmed394
absence of signs of cognitive impairment. No for-395
mal cognitive tests were performed in these family396
members.397
APOE genotype distribution in family structure398
All affected family members with for whom DNA399
was available (II.3, II.4, II.6, III.1) were homozy-400
gous for the APOE-ε4 allele. Of the seven unaffected401
family members from generation III for whom DNA402
was available, two were genotyped APOE-ε4/ε4, four403
were APOE-ε3/ε4, and one was APOE-ε3/ε3 (Sup-404
plementary Table 1A, Fig. 1).405
Given the frequency of all APOE genotype com-406
binations in the Dutch population, disease status of407
each family member by age, and the APOE geno-408
types for all individuals in generations II and III, we409
estimated a 65% chance that individuals I.1 and I.2410
are APOE-ε3/ε4 and APOE-ε4/ε4; and we estimated411
a 29% chance that individuals are both APOE-ε3/ε4412
(grey text in Fig. 1). Chances for other possible geno-413
types were negligible (Supplementary Table 1D).414
Likewise, we estimated a 76% chance that the APOE415
genotype of individual II.1, who was diagnosed with416
AD at 69, was APOE-ε4/ε4: and a 22% that it was417
APOE-ε3/ε4; chances for other possible genotypes418
were negligible (Supplementary Table 1E). Individ-419
ual II.8 has an 87% chance of being APOE-ε3/ε4 and420
a 12% chance of being APOE-ε3/ε3 (Supplementary421
Table 1F). Together, this provides support that this422
family included at least three generations ofAPOE-ε4 423
homozygotes. 424
Chances of developing AD in this family: 425
A statistical analysis 426
We evaluated the AD incidence in this family 427
w.r.t. empirical age at onset distributions extracted 428
from a Caucasian cohort, given APOE-genotype and 429
gender [10] (Supplementary Table 1C). The age 430
of AD onset in this family was significantly ear- 431
lier than expected: p = 0.0001 and p = 0.00006 using 432
respectively Fisher’s method and Stouffer’s method 433
of combining p-values. P-values remain significant 434
when we use the age at diagnosis, suggesting that 435
the finding is robust: p = 0.0290 and p = 0.0094 using 436
Fisher’s method and Stouffer’s method respectively 437
(Supplementary Table 1A). 438
Of note, the high incidence of AD may have 439
stimulated family members to visit our hospital for 440
cognitive testing. This may have introduced a bias 441
at the age at AD onset level that we cannot account 442
for. However, further family research revealed that 443
I.3 and I.4 (two siblings of I.2, who died of cancer at 444
age 55) were reported to have dementia at relatively 445
early ages at onset irrespective of family bias (61 and 446
73 years, respectively). 447
Exome sequencing outcome 448
To investigate whether additional genetic variants 449
occurred next to APOE-ε4 homozygosity, we per- 450
formed exome sequencing in two siblings with AD 451
(II.3, II.6), in one family member with preclinical 452
AD (III.1) and in the eldest participant without cog- 453
nitive complaints hitherto (III.2), all homozygous for 454
the APOE-ε4 allele. Exome sequencing revealed no 455
mutations in the PSEN1, PSEN2, and APP genes in 456
any of the family members. 457
We detected 16 variants that passed filtering, sev- 458
eral of which were rare and predicted to have a 459
deleterious effect on protein function (Supplemen- 460
tary Table 2). Two of these occurred in a gene 461
that might be functionally associated with amy- 462
loid processing or AD: (i) the missense variant 463
c.2021A>G, p.Asn674Ser, in exon 14 of the sortilin 464
related receptor 1 (SORL1) gene (NM.003105.5), 465
and (ii) c.707 C>T, p.Thr236Met, in exon 2 of 466
the teashirt zinc ﬁnger homeobox 3 (TSHZ3) gene 467
(NM.020856.2). The coverage of SORL1 and TSHZ3 468
captured with the exome kit was similar to the median 469
read depth over the whole exome. 470
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Fig. 4. p.Asn674Ser in the SORL1 protein. SORL1 is located on chromosome 11q23.2-q24.2 and codes for a 250-kDa membrane protein
with seven distinct domains. Blue, extracellular domains; green, intracellular domain; red, the p.Asn674Ser variant we identified in this
family; P, Pro-peptide; VPS10, vacuolar protein sorting domain 10; LDLR-B, LDL-receptor class B repeats; EGF, epidermal growth factor
precursor type repeat; LDLR-A, LDL-receptor class A repeats; FN-III, fibronectin type-III repeats; IC, intracellular component; LDL, low
density lipoprotein. The figure is based upon information from Uniprot (http://www.uniprot.org/uniprot/Q92673), transcript NM 003105.
This SORL1 variant was present in all three471
affected family members and the family member with472
preclinical AD, and in four unaffected family mem-473
bers (aged <60 years). The variant was not detected474
in any other subject in the Amsterdam Dementia475
cohort. One study detected the variant in a 63-year-476
old healthy female (control group n = 1938, MAF477
<0.001) [26], and the ExAC database reports only one478
heterozygous carrier of this variant (MAF <0.00001).479
The variant locus is at a highly conserved glycosyla-480
tion site in the VPS10 domain of SORL1 (Fig. 4), it481
has a CADD score of 23.6, and it is considered dele-482
terious by PolyPhen and Mutation Taster (although483
not by SIFT).484
The p.Thr236Met missense variant in TSHZ3 was485
detected in two of the three family members with AD,486
in the family member with preclinical AD and in one487
unaffected family member, who was also homozy-488
gous for APOE-ε4 but did not carry the SORL1489
variant. This TSHZ3 variant is located in a highly490
conserved amino acid, has a CADD score of 27.0491
and is predicted to be deleterious by PolyPhen, Muta-492
tion Taster, and SIFT. The variant was reported in 47493
individuals in the ExAC database (MAF <0.001).494
DISCUSSION495
We describe a family with an inheritance pattern496
suggestive of autosomal dominant AD of which all497
affected family members tested were homozygous for498
the APOE-4 allele. The age at AD onset was sig-499
nificantly earlier than expected, based on the APOE500
genotypes and gender of family-members, suggesting501
that next to a high load of APOE-ε4, this family is rel-502
atively enriched with other AD-associated elements.503
Whole exome sequencing revealed two additional504
variants co-inherited with APOE-4 homozygosity505
that might disturb A processing: a rare missense 506
variant leading to p.Asn674Ser in the SORL1 protein 507
and a rare missense variant leading to p.Thr236Met 508
in the TSHZ3 protein. We speculate these SORL1 509
and TSHZ3 variants increased the penetrance of AD 510
in this family. Without APOE-4 homozygosity, nei- 511
ther variants may reach full AD penetrance, as can 512
be observed in the pedigree where several APOE-4 513
heterozygous or APOE-4 negative family members 514
carry the SORL1 and/or TSHZ3 gene variants with- 515
out having the disease. It should be noted however, 516
that these family members are still young, and may 517
develop AD at a later age, such that we cannot exclude 518
the possibility that either variant confers full AD pen- 519
etrance. For the same reason we cannot (yet) identify 520
the effect of APOE-4 gene dosage, by analyzing to 521
what extent impaired SORL1 and/or TSHZ3 modu- 522
lates AD penetrance in a background of heterozygous 523
APOE-4. Moreover, this family carried several addi- 524
tional rare genetic variants, some of which were 525
predicted to have a deleterious effect on protein func- 526
tion. Although these variants map in genes that are 527
currently not associated with AD, we cannot a priori 528
rule out that they modulate AD susceptibility in this 529
family. 530
TSHZ3 may modulate Aβ processing 531
The rare variant detected in TSHZ3 is predicted 532
to have a damaging effect on protein function by 533
all effect predictor algorithms, and has a relatively 534
high CADD score of 27. Although evidence is lim- 535
ited, this rare variant might complicate A processing 536
since the TSHZ3 protein has been found to bind to 537
FE65, an adaptor protein that can modulate APP 538
trafficking and/or processing [27]. TSHZ3 downreg- 539
ulates Caspase 4, which is involved cell death induced 540
by cytotoxic APP peptides [28–30]. However, more 541
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evidence is needed to link disturbed TSHZ3 protein542
function to AD.543
Impaired SORL1 increases Aβ production544
In sharp contrast with TSHZ3, evidence has accu-545
mulated that impaired SORL1 function associates546
with AD: common genetic polymorphisms in the547
SORL1 locus were associated with AD in a genome-548
wide association studies [31], disruptive variants549
were only detected in AD cases and not in con-550
trols [26] and rare pathogenic SORL1 variants were551
found to increase the risk for early onset AD by five-552
fold [32].553
Functional studies suggested that the SORL1 sort-554
ing receptor has a dual function: (i) SORL1 binds555
APP and prevents it from processing into A [33],556
and (ii) SORL1 binds newly synthesized extracellu-557
lar A and targets it to the lysosome for degradation558
[34]. To exert these functions, SORL1 has two impor-559
tant protein domains: an APP-binding complement560
type repeat domain, and an A-binding VPS-10561
domain [33].562
The p.Asn674Ser variant in SORL1 that we563
detected in this family affects a highly conserved564
N-glycosylation site in the VPS10 domain, which is565
important for proper protein folding and for protein-566
protein interaction [33]. Previously, variants that map567
in the VPS10 domain (p.Glu270Lys, p.Ala528Thr)568
were associated with impaired retrograde sorting of569
APP and enhanced A production when expressed570
in cells [35], suggesting that a wild-type VPS10571
domain is essential for proper A processing. We572
speculate that the p.Asn674Ser change detected in573
this family may at disrupt the A-binding capac-574
ity of SORL1, resulting in less efficient lysosomal575
degradation of A [34].576
Combined effect of APOE-4 homozygosity,577
impaired SORL1 and impaired TSHZ3578
Experimental studies suggest that the proteins579
encoded by the APOE and SORL1 genes function-580
ally interact [36]. By binding to the complement581
type repeats of the SORL1 protein, ApoE4 reduced582
the APP-binding-capacity of SORL1 [37]. Further-583
more, overexpression of SORL1 increases the uptake584
of extracellular A in an ApoE-isoform-dependent585
manner, most efficiently in the presence of the 4586
isoform [36]. Therefore, the clearance of A is587
expected to be more dependent on SORL1 expres-588
sion in APOE-4 carriers than in individuals with no589
APOE-4 alleles. A combination of homozygous or 590
heterozygous ApoE4 and dysfunctional SORL1 may 591
therefore lead to abnormal increases in extracellular 592
A loads, which may underlie the neurodegenerative 593
processes in this family. 594
Effect of the genotype on phenotype 595
Homozygous APOE-4 carriers typically present 596
with an amnestic phenotype, however the AD pheno- 597
type of the five affected family members for whom 598
detailed clinical data were available, was heteroge- 599
neous: The age at onset differed between affected 600
family members and ranged between 61 and 74 years, 601
which fits with the relatively early age of disease 602
onset associated with APOE-4 homozygosity [38]. 603
Homozygous APOE-4 and disrupted SORL1 are 604
both associated with CAA, presumably as a result 605
of the less effective A clearance [39–41]. Indeed, 606
two family members with AD had extensive microb- 607
leeds and CAA, while two others remained free of 608
microbleeds. 609
Both APOE and SORL1 are involved in choles- 610
terol metabolism/transport, and APOE-4 carriers 611
have been found to have increased cholesterol lev- 612
els [42, 43]. Indeed, three affected family members 613
were diagnosed with hypercholesterolemia in this 614
family. Likewise, the EEG pattern of APOE-4 allele 615
carrier-patients shows a greater decrease of alpha 616
activity than non-APOE-4 carrier-patients [44, 45]. 617
However, in this family, neither microbleeds/CAA, 618
hypercholesterolemia or EEG patterns cosegregated 619
with APOE-4 homozygosity and/or the SORL1 620
variant. 621
Conclusion 622
We hypothesize that the convergence of multiple 623
genetic factors that disturb the A processing path- 624
ways over several generations results in an autosomal 625
dominant like inheritance pattern of AD in this family. 626
Extracellular A load might be abnormally increased 627
as a result of the concerted effects of (i) ineffective 628
clearance of extracellular A from the brain by the 629
ApoE4 protein isoform, and (ii) impaired uptake of 630
extracellular A for lysosomal degradation due to a 631
disturbed VPS10 domain of the SORL1 protein. It is 632
possible that a disturbed TSHZ3 function might have 633
further contributed to impaired APP regulation, but 634
compared to ApoE4 and SORL1, the evidence for an 635
association of disrupted TSHZ3 with AD is currently 636
very limited. Moreover, other genetic variants that 637
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were left undetected with our analysis strategy might638
have further influenced disease penetrance.639
Given these findings, the currently unaffected fam-640
ily member who is homozygous for APOE-4 and641
who carries the SORL1 variant may be at the high-642
est risk to develop AD. Follow-up of this family in643
the future will resolve these speculations. We expect644
that this polygenic model, possibly involving other645
genetic variants, might also explain autosomal dom-646
inant inheritance patterns in other APOE-4 positive647
families.648
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